留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

迟发性运动障碍的临床诊治进展

王喜喜 万新华

王喜喜, 万新华. 迟发性运动障碍的临床诊治进展[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2021-0717
引用本文: 王喜喜, 万新华. 迟发性运动障碍的临床诊治进展[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2021-0717
WANG Xixi, WAN Xinhua. Clinical Diagnosis and Treatment of Tardive Dyskinesia[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2021-0717
Citation: WANG Xixi, WAN Xinhua. Clinical Diagnosis and Treatment of Tardive Dyskinesia[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2021-0717

迟发性运动障碍的临床诊治进展

doi: 10.12290/xhyxzz.2021-0717
基金项目: 

ANO3突变通过SLACK-FMRP-DRD1通路参与肌张力障碍发病的机制研究

详细信息
    通讯作者:

    万新华,E-mail:wxhpumch@163.com

  • 中图分类号: R746;R741.02

Clinical Diagnosis and Treatment of Tardive Dyskinesia

Funds: 

ANO3 Mutation Participates in the Pathogenesis of Dystonia Through SLACK-FMRPDRD1 Pathway

  • 摘要: 迟发性运动障碍(tardive dyskinesis,TD)是与长期服用多巴胺受体阻滞剂(dopamine receptor blocking agents,DRBA)相关的一种异常不自主运动,可累及面颈部,引起伸舌、咀嚼、噘嘴、歪颌或转颈,也可累及四肢和躯干,表现为舞蹈样动作。临床上最常见病因的是抗精神病药物(antipsychotic drugs,APD)的使用。与TD相关的危险因素包括APD种类、用药剂量和时间、年龄和性别,遗传因素也发挥一定作用。目前研究较多的TD相关基因为CYP2D6、DRD2、DRD3、HTR2A、HTR2C、VMAT2、MnSOD、HSPG2。TD的发病机制尚不明确,主要有多巴胺受体超敏学说、氧化应激学说和突触可塑性失调学说。临床上TD较难治疗,预防至关重要,一线治疗是氘代丁苯那嗪和戊苯那嗪——新型囊泡单胺转运体2(Vesicular monoamine transporter 2,VMAT2)抑制剂,其他可能有效的口服药包括氯硝西泮、金刚烷胺和银杏叶提取物,对于口服药反应不佳的患者可选择肉毒毒素局部注射(botulinum toxin local injection)和深部脑刺激(deep brain stimulation,DBS)。
  • [1] Zutshi D, Cloud LJ, Factor SA. Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents:Experience from a University-based Movement Disorder Clinic[J].Tremor Other Hyperkinet Mov (N Y), 2014, 4:266.
    [2] Carbon M, Hsieh CH, Kane JM, et al. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use:A Meta-Analysis[J]. J Clin Psychiatry, 2017, 78:e264-e78.
    [3] Schonecker M. Paroxysmal dyskinesia as the effect of megaphen[J]. Nervenarzt, 1957, 28:550-553.
    [4] Vinuela A, Kang UJ. Reversibility of tardive dyskinesia syndrome[J].Tremor Other Hyperkinet Mov (N Y), 2014, 4:282.
    [5] Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications[J]. J Clin Psychiatry, 1993, 54:133-139.
    [6] Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients[J]. Arch Gen Psychiatry, 1995, 52:756-765.
    [7] Patel RS, Mansuri Z, Chopra A. Analysis of risk factors and outcomes in psychiatric inpatients with tardive dyskinesia:A nationwide case-control study[J]. Heliyon, 2019, 5:e01745.
    [8] Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics:a retrospective data analysis[J]. BMC Neurol, 2019, 19:174.
    [9] Saklad SR. Identifying Tardive Dyskinesia:Risk Factors, Functional Impact, and Diagnostic Tools[J]. J Clin Psychiatry, 2020, 81:TV18059BR1C.
    [10] Uludag K, Wang DM, Goodman C, et al. Prevalence, clinical correlates and risk factors associated with Tardive Dyskinesia in Chinese patients with schizophrenia[J]. Asian J Psychiatr, 2021, 66:102877.
    [11] van Harten PN, Tenback DE. Tardive dyskinesia:clinical presentation and treatment[J]. Int Rev Neurobiol, 2011, 98:187-210.
    [12] Meltzer HY. Update on typical and atypical antipsychotic drugs[J]. Annu Rev Med, 2013, 64:393-406.
    [13] Blanchet PJ. A Focused Update on Tardive Dyskinesia[J]. Can J Neurol Sci, 2020, 47:747-755.
    [14] Rao AS, Camilleri M. Review article:metoclopramide and tardive dyskinesia[J]. Aliment Pharmacol Ther, 2010, 31:11-9.
    [15] Alford EL, Wheless JW, Phelps SJ. Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients[J]. J Pediatr Pharmacol Ther, 2015, 20:260-289.
    [16] Cornett EM, Novitch M, Kaye AD, et al. Medication-Induced Tardive Dyskinesia:A Review and Update[J]. Ochsner J, 2017, 17:162-174.
    [17] Caroff SN. Recent Advances in the Pharmacology of Tardive Dyskinesia[J].Clin Psychopharmacol Neurosci, 2020, 18:493-506.
    [18] Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity:a hypothesis[J]. Mov Disord, 2012, 27:1205-1215.
    [19] Seeman P, Tinazzi M. Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2013, 44:178-183.
    [20] Frei K. Tardive dyskinesia:Who gets it and why[J]. Parkinsonism Relat Disord, 2019, 59:151-154.
    [21] Zai CC, Maes MS, Tiwari AK, et al. Genetics of tardive dyskinesia:Promising leads and ways forward[J]. J Neurol Sci, 2018, 389:28-34.
    [22] Koola MM, Tsapakis EM, Wright P, et al. Association of tardive dyskinesia with variation in CYP2D6:Is there a role for active metabolites?[J]. J Psychopharmacol, 2014, 28:665-670.
    [23] Lu JY, Tiwari AK, Freeman N, et al. Liver enzyme CYP2D6 gene and tardive dyskinesia[J]. Pharmacogenomics, 2020, 21:1065-1072.
    [24] Vaiman EE, Shnayder NA, Novitsky MA, et al. Candidate Genes Encoding Dopamine Receptors as Predictors of the Risk of Antipsychotic-Induced Parkinsonism and Tardive Dyskinesia in Schizophrenic Patients[J]. Biomedicines, 2021, 9:879
    [25] Tsai HT, Caroff SN, Miller DD, et al. A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial[J]. Am J Med Genet B Neuropsychiatr Genet, 2010, 153B:336-340.
    [26] Zai CC, Tiwari AK, Mazzoco M, et al. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia[J]. J Psychiatr Res, 2013, 47:1760-1765.
    [27] Segman RH, Heresco-Levy U, Finkel B, et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia:additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility[J]. Psychopharmacology(Berl), 2000, 152:408-413.
    [28] Syu A, Ishiguro H, Inada T, et al. Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia[J]. Neuropsychopharmacology, 2010, 35:1155-1164.
    [29] Greenbaum L, Alkelai A, Zozulinsky P, et al. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations[J]. Pharmacogenomics J, 2012, 12:513-520.
    [30] Zai CC, Lee FH, Tiwari AK, et al. Investigation of the HSPG2 Gene in Tardive Dyskinesia-New Data and Meta-Analysis[J]. Front Pharmacol, 2018, 9:974.
    [31] Arinami T, Inada T. Genome-wide association analyses for neuroleptic-induced tardive dyskinesia[J]. Nihon Shinkei Seishin Yakurigaku Zasshi, 2011, 31:155-162.
    [32] Aberg K, Adkins DE, Bukszár J, et al. Genomewide association study of movement-related adverse antipsychotic effects[J]. Biol Psychiatry, 2010, 67:279-282.
    [33] Inada T, Koga M, Ishiguro H, et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia[J]. Pharmacogenet Genomics, 2008, 18:317-323.
    [34] Levchenko A, Kanapin A, Samsonova A, et al. A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2021, 105:110134.
    [35] Ayhan F, Konopka G. Regulatory genes and pathways disrupted in autism spectrum disorders[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2019, 89:57-64.
    [36] Li W, Pozzo-Miller L. Dysfunction of the corticostriatal pathway in autism spectrum disorders[J]. J Neurosci Res, 2020, 98:2130-2147.
    [37] Lam M, Chen CY, Li Z, et al. Comparative genetic architectures of schizophrenia in East Asian and European populations[J]. Nat Genet, 2019, 51:1670-1678.
    [38] Lam M, Hill WD, Trampush JW, et al. Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways[J]. Am J Hum Genet, 2019, 105:334-350.
    [39] Sollis E, Graham SA, Vino A, et al. Identification and functional characterization of de novo FOXP1 variants provides novel insights into the etiology of neurodevelopmental disorder[J]. Hum Mol Genet, 2016, 25:546-557.
    [40] Lim K, Lam M, Zai C, et al. Genome wide study of tardive dyskinesia in schizophrenia[J]. Transl Psychiatry, 2021, 11:351.
    [41] Erbe S.Prevention and Treatment of Antipsychotic-induced Tardive Dyskinesia[J].Fortschr Neurol Psychiatr, 2019, 87:217-224.
    [42] Caroff SN, Leong SH, Roberts CB, et al. Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia[J]. J Clin Psychopharmacol, 2020, 40:373-380.
    [43] Jain R, Correll CU. Tardive Dyskinesia:Recognition, Patient Assessment, and Differential Diagnosis[J]. J Clin Psychiatry, 2018, 79:nu17034ah1c.
    [44] Solmi M, Pigato G, Kane JM, et al. Clinical risk factors for the development of tardive dyskinesia[J]. J Neurol Sci, 2018, 389:21-27.
    [45] Caroff SN, Citrome L, Meyer J, et al. A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia[J]. J Clin Psychiatry, 2020, 81:19cs12983.
    [46] Khorassani F, Luther K, Talreja O. Valbenazine and deutetrabenazine:Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia[J]. Am J Health Syst Pharm, 2020, 77:167-174.
    [47] Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment Recommendations for Tardive Dyskinesia[J]. Can J Psychiatry, 2019, 64:388-399.
    [48] Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia[J]. Am J Psychiatry, 2020, 177:868-872.
    [49] Margolius A, Fernandez HH. Current treatment of tardive dyskinesia[J]. Parkinsonism Relat Disord, 2019, 59:155-160.
    [50] Arya D, Khan T, Margolius AJ, et al. Tardive Dyskinesia:Treatment Update[J]. Curr Neurol Neurosci Rep, 2019, 19:69.
    [51] Lindenmayer JP, Verghese C, Marder SR, et al. A long-term, open-label study of valbenazine for tardive dyskinesia[J]. CNS Spectr, 2021, 26:345-353.
    [52] Debrey SM, Goldsmith DR. Tardive Dyskinesia:Spotlight on Current Approaches to Treatment[J]. Focus (Am Psychiatr Publ), 2021, 19:14-23.
    [53] Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia:a practical GABAmimetic strategy[J]. Am J Psychiatry, 1990, 147:445-451.
    [54] Angus S, Sugars J, Boltezar R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia[J]. J Clin Psychopharmacol, 1997, 17:88-91.
    [55] Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia:a randomized, doubleblind, placebo-controlled study[J]. Clin Neuropharmacol, 2010, 33:271-275.
    [56] Zhang WF, Tan YL, Zhang XY, et al. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia:a randomized, double-blind, placebo-controlled trial[J]. J Clin Psychiatry, 2011, 72:615-621.
    [57] Pouclet-Courtemanche H, Rouaud T, Thobois S, et al. Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia[J]. Neurology, 2016, 86:651-659.
    [58] Gruber D, Südmeyer M, Deuschl G, et al. Neurostimulation in tardive dystonia/dyskinesia:A delayed start, sham stimulation-controlled randomized trial[J]. Brain Stimul, 2018, 11:1368-1377.
    [59] Factor SA. Management of Tardive Syndrome:Medications and Surgical Treatments[J]. Neurotherapeutics, 2020, 17:1694-1712.
    [60] Chen CY, Chiang HL, Fuh JL. Tardive syndrome:An update and mini-review from the perspective of phenomenology[J]. J Chin Med Assoc, 2020, 83:1059-1065.
  • 加载中
计量
  • 文章访问数:  28
  • HTML全文浏览量:  2
  • PDF下载量:  3
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-10-29
  • 网络出版日期:  2022-02-15

目录

    /

    返回文章
    返回